The pharmaceutical industry—which for two decades has given twice as much in campaign donations
to Republicans as Democrats—organized a panel composed mostly of Democrats this month in Indianapolis
to argue its position on health care reform.
Favorable article in prestigious journal could draw attention to Carmel biotech startup.
A state law that went into effect July 1 attempts to attract young physicians and mental health practitioners to underserved
areas by forgiving part of their student loans. But Indiana’s budget woes prevented lawmakers from allocating funds
to support the program.
Health care marketers can adapt to, and even use to their advantage, the online search habits of consumers.
Understanding when and why people search for specific health-related terms is vital to attracting more
visitors (i.e. patients) to a Web site.
Biomet Inc. yesterday reported a $170.9 million loss in its fiscal fourth quarter as the result of more than $300 million
in special charges.
The Indianapolis Colts have become one of the first National Football League teams to sell a corporate sponsorship patch
on players’ practice jersey.
Eli Lilly and Co. finally won approval today from U.S. regulators to sell prasugrel, its highly anticipated blood thinner,
according to Bloomberg News.
Carmel-based Conseco Inc., still a bit strapped for cash, brought in a reinsurance company to shoulder some of the risk
of its life insurance policies. Minnesota-based Wilton Reassurance Co. will pay $57.5 million to Conseco as a ceding
commission to co-insure and administer 104,000 policies held by Conseco subsidiaries.
Purdue University researcher Philip Low, also the chief science officer for West Lafayette-based Endocyte Inc., has developed
a prostate cancer “homing device” to help anti-cancer agents specifically target prostate
cancer tumors.
Local businessman J.B. Carlson contends the $15 million life insurance policy he took out on Stephen Hilbert’s mother-in-law
was legitimate, because she served on his firm’s board and was a key decision-maker. The mother-in-law, Germaine
“Suzy” Tomlinson, died at age 74 last September—just 32 months after the policy was issued.
Drugmakers Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said yesterday that the U.S. Food and Drug Administration
has accepted their application for the once-a-week diabetes drug exenatide.
Two Indianapolis benefits consulting firms have finalized their merger, the companies announced this morning. Terms of the
deal between Benefit Associates Inc. and Benefit Consultants Inc., in the works since March, were not disclosed.
Eli Lilly and Co.’s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales of
the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer
for certain patients, Lilly announced today.
Once again, Indianapolis-based Eli Lilly and Co. is running in the lead pack in dollars spent to bend ears on Capitol Hill. And that was even before the health care reform debate got rolling.
The Indiana Minority Supplier Development Council has made life sciences companies its latest target—part of an even larger effort to attract minorities to the burgeoning life sciences industry under
way on a national scale.
Private equity firms have a reputation as ruthless acquirers. They slash fat and jettison sluggish product lines, all in a quest to wring out higher profits and grow the parts of the business with the most potential. For Indianapolis-based Dow AgroSciences—or at least for its 1,200 local employees—a buyer like that would be a godsend. […]
A new communications post at Eli Lilly gives former mayor Bart Peterson an opportunity to meld his experiences in the public
and private sectors.
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—a model that’s low-cost
and can spread around the world.
While Eli Lilly and Co. continues to work with a biotech firm on the diabetes medicine Byetta, it’s developing a potential
competitor to Byetta all on its own.
The CEO of the Wishard Foundation resigned last month, prompting the fund-raising arm of Wishard Health Services to tap consulting
firm Johnson Grossnickle & Associates for a replacement.
